DYN EBITDA | Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. EBITDA

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of the cash a company's operations generate before accounting charges for wearing out its assets. Here it is operating income plus the filed depreciation and amortization, not a figure the company adjusted itself. Higher EBITDA means more operating profit before those charges. It is not an official accounting (GAAP) measure and does not subtract capital spending, interest or tax, so it does not show what those obligations cost.

Dyne Therapeutics, Inc. ebitda for the quarter ending 2026-06-30 was -$181.06M, a change of -$65.77M year-over-year.
Dyne Therapeutics, Inc. ebitda for the quarter ending 2026-03-31 was -$124.73M, a change of -$2.86M year-over-year.
Dyne Therapeutics, Inc. ebitda for the quarter ending 2025-12-31 was -$115.61M, a change of -$18.95M year-over-year.
Dyne Therapeutics, Inc. ebitda for the quarter ending 2025-09-30 was -$113.39M, a change of -$8.22M year-over-year.
Dyne Therapeutics, Inc. ebitda for fiscal 2025 was -$466.14M, a change of -$123.92M from fiscal 2024.
Dyne Therapeutics, Inc. ebitda for fiscal 2024 was -$342.21M, a change of -$101.72M from fiscal 2023.
Dyne Therapeutics, Inc. ebitda for fiscal 2023 was -$240.49M, a change of -$71.21M from fiscal 2022.
Dyne Therapeutics, Inc. ebitda for fiscal 2022 was -$169.28M, a change of -$20.34M from fiscal 2021.

Available history: 2019-09-30 to 2026-06-30
Data captured: 2026-06-30

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$181.06M	-$181.66M	$600,000.00	(m)	(m)	$1.51M*	-$130.29M*	(m)	$152.17M	(m)	(m)
2026-03-31	Reported	-$124.73M	-$125.28M	$550,000.00	(m)	(m)	$221.00K	-$144.92M	(m)	$100.89M	(m)	(m)
2025-12-31	Reported	-$115.61M	-$116.13M	$521,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$113.39M	-$113.89M	$500,000.00	(m)	(m)	$395.00K*	-$90.78M*	(m)	$97.22M	(m)	(m)
2025-06-30	Reported	-$115.29M	-$115.79M	$500,000.00	(m)	(m)	$60.00K*	-$94.70M*	(m)	$99.24M	(m)	(m)
2025-03-31	Reported	-$121.87M	-$122.37M	$502,000.00	(m)	(m)	$981.00K	-$105.89M	(m)	$106.45M	(m)	(m)
2024-12-31	Reported	-$96.66M	-$97.11M	$450,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$105.17M	-$105.57M	$400,000.00	(m)	(m)	$253.00K*	-$74.63M*	(m)	$92.80M	(m)	(m)
2024-06-30	Reported	-$71.56M	-$71.96M	$400,000.00	(m)	(m)	$857.00K*	-$54.87M*	(m)	$62.26M	(m)	(m)
2024-03-31	Reported	-$68.77M	-$69.16M	$386,000.00	(m)	(m)	$191.00K	-$78.54M	(m)	$44.54M	(m)	(m)
2023-12-31	Reported	-$67.29M	-$67.69M	$399,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$61.87M	-$62.27M	$400,000.00	(m)	(m)	$167.00K*	-$50.60M*	(m)	$55.25M	(m)	(m)
2023-06-30	Reported	-$66.34M	-$66.74M	$400,000.00	(m)	(m)	$250.00K*	-$55.64M*	(m)	$59.13M	(m)	(m)
2023-03-31	Reported	-$45.05M	-$45.46M	$412,000.00	(m)	(m)	$230.00K	-$46.91M	(m)	$37.54M	(m)	(m)
2022-12-31	Reported	-$39.74M	-$40.15M	$401,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$41.88M	-$42.28M	$400,000.00	(m)	(m)	$886.00K*	-$42.80M*	(m)	$34.67M	(m)	(m)
2022-06-30	Reported	-$52.26M	-$52.76M	$500,000.00	(m)	(m)	$261.00K*	-$30.91M*	(m)	$46.66M	(m)	(m)
2022-03-31	Reported	-$35.36M	-$35.78M	$425,000.00	(m)	(m)	$1.40M	-$50.74M	(m)	$28.24M	(m)	(m)
2021-12-31	Reported	-$51.62M	-$51.96M	$341,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$42.47M	-$42.77M	$300,000.00	(m)	(m)	$881.00K*	-$26.95M*	(m)	$36.51M	(m)	(m)
2021-06-30	Reported	-$29.97M	-$30.17M	$200,000.00	(m)	(m)	$738.00K*	-$46.15M*	(m)	$23.87M	(m)	(m)
2021-03-31	Reported	-$24.9M	-$25.13M	$238,000.00	(m)	(m)	$9.00K	-$18.39M	(m)	$18.63M	(m)	(m)
2020-12-31	Reported	-$28.38M	-$28.6M	$217,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$13.32M	-$13.52M	$200,000.00	(m)	(m)	$156.00K*	-$11.89M*	(m)	$9.68M	(m)	(m)
2020-06-30	Reported	-$8.48M	-$8.68M	$200,000.00	(m)	(m)	$71.00K*	-$7.30M*	(m)	$7.33M	(m)	(m)
2020-03-31	Reported	-$7.7M	-$7.85M	$150,000.00	(m)	(m)	$211.00K	-$7.29M	(m)	$6.09M	(m)	(m)
2019-12-31	Reported	-$5.32M	-$5.47M	$146,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$3.53M	-$3.63M	$100,000.00	(m)	(m)	(m)	(m)	(m)	$2.98M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$466.14M	-$468.18M	$2.05M	(m)	(m)	$1.92M	-$403.21M	(m)	$398.33M	(m)	$0.00
2024-12-31	Reported	-$342.21M	-$343.89M	$1.67M	(m)	(m)	$2.38M	-$292.37M	(m)	$281.41M	(m)	$0.00
2023-12-31	Reported	-$240.49M	-$242.16M	$1.67M	(m)	(m)	$729.00K	-$188.16M	(m)	$210.76M	(m)	$0.00
2022-12-31	Reported	-$169.28M	-$170.96M	$1.68M	(m)	(m)	$3.07M	-$153.65M	(m)	$142.76M	(m)	(m)
2021-12-31	Reported	-$148.94M	-$150.03M	$1.09M	(m)	(m)	$3.62M	-$119.56M	(m)	$121.31M	(m)	(m)
2020-12-31	Reported	-$57.95M	-$58.65M	$700,000.00	(m)	(m)	$1.16M	-$46.51M	(m)	$45.20M	(m)	(m)
2019-12-31	Reported	-$13.56M	-$13.83M	$271,000.00	(m)	(m)	$1.65M	-$11.83M	(m)	$11.04M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Arcus Biosciences, Inc. (RCUS)	United States	$3.188B	-8.52
Arcutis Biotherapeutics, Inc. (ARQT)	United States	$3.303B	115.47
Enliven Therapeutics, Inc. (ELVN)	United States	$3.307B	-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)	United States	$3.361B	-13.15
PRECIGEN, INC. (PGEN)	United States	$2.757B	-12.94
NewAmsterdam Pharma Co N.V. (NAMS)		$2.719B	-15.37
MBX Biosciences, Inc. (MBX)	United States	$2.664B	-25.36
IDEAYA Biosciences, Inc. (IDYA)	United States	$3.540B	-20.52
Organon & Co. (OGN)	United States	$3.603B	17.03
Disc Medicine, Inc. (IRON)	United States	$2.553B	-11.40